With more than three weeks left in the first quarter, the value of med-tech IPOs for 2025 already exceeds the funds raised ...

Lysine demethylase 6A (KDM6A) is a demethylase that plays a key role at regulating developmental gene expression signatures ...

A slow-down in EU medical device audits due to the long-delayed transition to the EU Medical Device Regulation is leading to ...

Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer with a high mortality rate and characterized by ...

The first treatment for macular telangiectasia type 2 is set to enter the market following U.S. FDA approval of NT-501 ...

A new multi-omics approach to unpicking how noncoding gene variants influence the development of common chronic diseases has ...

Researchers from Revolo Biotherapeutics Ltd. recently presented preclinical data for IRL-201104, a clinical-stage ...

Ajax Health LLC, with backing from the $4 billion KKR Health Care Strategic Growth Fund II, and Boston Scientific Corp.

Bioheng Therapeutics US LLC has obtained IND approval from the FDA for CTD-402, a CD7-targeted universal CAR T-cell therapy, ...

The BioWorld Neurological Diseases Index closed 2024 down 20.27%, extending its decline from -13.4% at the end of November. After falling to -12.2% in April, the index briefly rebounded, narrowing ...

Biopharma companies raised $2.98 billion through 59 transactions in February 2025, down from $5.91 billion across 93 deals in January. The year is off to a slower start compared to 2023, with the ...

Boehringer Ingelheim GmbH terminated its second metabolic dysfunction-associated steatohepatitis (MASH) alliance on March 6, ending an $870 million license agreement inked with Yuhan Corp. for dual ...